Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells $195,000.00 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Michael Chi sold 7,500 shares of the business’s stock in a transaction dated Thursday, December 19th. The stock was sold at an average price of $26.00, for a total transaction of $195,000.00. Following the sale, the insider now owns 193,601 shares in the company, valued at $5,033,626. This trade represents a 3.73 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Michael Chi also recently made the following trade(s):

• On Tuesday, December 10th, Michael Chi sold 7,259 shares of Hims & Hers Health stock. The stock was sold at an average price of $32.25, for a total value of $234,102.75.
• On Monday, December 2nd, Michael Chi sold 2,054 shares of Hims & Hers Health stock. The shares were sold at an average price of $33.56, for a total value of $68,932.24.
• On Friday, October 25th, Michael Chi sold 17,304 shares of Hims & Hers Health stock. The stock was sold at an average price of $22.00, for a total value of $380,688.00.
• On Monday, October 21st, Michael Chi sold 7,500 shares of Hims & Hers Health stock. The shares were sold at an average price of $22.20, for a total value of $166,500.00.

Hims & Hers Health Stock Performance

HIMS stock opened at $28.15 on Thursday. The firm has a 50 day simple moving average of $26.15 and a 200 day simple moving average of $21.41. Hims & Hers Health, Inc. has a 52 week low of $8.09 and a 52 week high of $35.02. The stock has a market cap of $6.15 billion, a P/E ratio of 63.98 and a beta of 1.25.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $401.56 million during the quarter, compared to analyst estimates of $382.20 million. During the same quarter last year, the business posted ($0.04) EPS. The company’s revenue for the quarter was up 77.1% on a year-over-year basis. Sell-side analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of HIMS. Nisa Investment Advisors LLC lifted its holdings in shares of Hims & Hers Health by 679.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after buying an additional 1,603 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Hims & Hers Health by 67.5% in the second quarter. Bank of New York Mellon Corp now owns 678,602 shares of the company’s stock valued at $13,701,000 after acquiring an additional 273,473 shares during the last quarter. State of Michigan Retirement System grew its position in Hims & Hers Health by 177.8% in the second quarter. State of Michigan Retirement System now owns 500,000 shares of the company’s stock worth $10,095,000 after acquiring an additional 320,000 shares in the last quarter. Allspring Global Investments Holdings LLC increased its stake in shares of Hims & Hers Health by 322.9% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 52,312 shares of the company’s stock worth $1,056,000 after purchasing an additional 39,943 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Hims & Hers Health by 33.0% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 27,830 shares of the company’s stock valued at $562,000 after purchasing an additional 6,912 shares in the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

HIMS has been the subject of a number of research analyst reports. Piper Sandler reissued a “neutral” rating and issued a $21.00 price target (up from $18.00) on shares of Hims & Hers Health in a report on Tuesday, November 5th. Morgan Stanley started coverage on shares of Hims & Hers Health in a report on Tuesday, December 17th. They set an “overweight” rating and a $42.00 target price for the company. TD Cowen reaffirmed a “buy” rating and issued a $28.00 price target on shares of Hims & Hers Health in a report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised their price objective on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, November 6th. Finally, Bank of America lowered Hims & Hers Health from a “buy” rating to an “underperform” rating and cut their target price for the stock from $32.00 to $18.00 in a research report on Thursday, November 14th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $22.80.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.